Skip to content
lifestyle.paraskevas.net
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
BioNxt Solutions Inc.
BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline
August 4, 2026
BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway
July 6, 2026
BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF
June 15, 2026
BioNxt Advances Semaglutide ODF Program into Active Pharmaceutical Development
May 19, 2026
BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS)
April 14, 2026
BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries
April 7, 2026
BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy
March 30, 2026
BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe
March 17, 2026
BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis
February 17, 2026
BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery
February 11, 2026
1
2
Next Page
→